Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004) [Phase 3]
A Phase 3 clinical trial evaluating Calderasib (MK-1084) in combination with Pembrolizumab (MK-3475) for KRAS G12C mutant non-small cell lun…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer [Phase 3]
Phase 3 trial evaluating AZD6738 (ceralasertib) in combination with immunotherapy for Non-Small Cell Lung Cancer; the study is currently ACT…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones [Phase 1]
Phase 1 safety study of Sn-117m-DTPA for cancers that have spread to bone, including metastatic breast, lung, and prostate cancers; the tria…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Volrustomig Priming Regimens Exploratory Phase II Platform Study [Phase 2]
AstraZeneca's exploratory Phase II platform trial is evaluating Volrustomig priming regimens in non-small cell lung cancer, currently recrui…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: National Cancer Institute "Cancer Moonshot Biobank"
National Cancer Institute's Cancer Moonshot Biobank update outlines the trial's status and scope, indicating the study is active but not rec…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer [Phase 1, Phase 2]
A Phase 1/2 trial investigating the combination of amivantamab and olomorasib in participants with metastatic non-small cell lung cancer is …
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Grid Radiation Therapy for the Treatment of Stage IV Non-Small Cell Lung Cancer [Phase 2]
A Phase 2 clinical trial evaluating grid radiation therapy for stage IV non-small cell lung cancer is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer [Phase 1, Phase 2]
This is an update on a Phase 1/2 clinical trial evaluating the combination of amivantamab and capmatinib for unresectable metastatic non-sma…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer [Phase 1]
A Phase 1 clinical trial update for lazertinib as a monotherapy or in combination with amivantamab in adults with advanced non-small cell lu…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation [Phase 1, Phase 2]
This clinical trial update announces an ongoing Phase 1/2 study evaluating sotorasib in combination with trastuzumab deruxtecan for KRAS G12…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC [Phase 1]
This clinical trial update describes a Phase Ib safety study of trastuzumab deruxtecan in combination with immunotherapy agents, with or wit…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer
This clinical trial registry entry describes a study evaluating treatments for chemotherapy-induced peripheral neuropathy in cancer patients…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: ResQ1010-NSCLC: NAI + Chemoimmunotherapy vs Chemoimmunotherapy for First-Line Advanced/Metastatic NSCLC [Phase 3]
A Phase 3 trial update describing ResQ1010 combined with chemoimmunotherapy versus chemoimmunotherapy alone as first-line treatment for adva…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy [Phase 1, Phase 2]
Clinical trial evaluating oral 7HP349 (Alintegimod) in combination with ipilimumab, followed by nivolumab monotherapy, in patients with adva…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan [Phase 1]
Phase 1 trial evaluating the safety, adverse events, and pharmacokinetics of Azirkitug alone or in combination with Budigalimab, Bevacizumab…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC [Phase 2]
This clinical trial update describes a Phase II efficacy study of repotrectinib for ROS1-rearranged advanced non-small cell lung cancer in f…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer [Phase 1]
A Phase 1 clinical trial update evaluating the combination of MLN0128 (TAK-228) and AZD9291 in EGFR mutation-positive advanced non-small cel…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) ENTIRETY
Takeda-sponsored clinical trial evaluating brigatinib as a preferred first-line therapy for adults with non-small cell lung cancer is curren…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative [Phase 2, Phase 3]
A phase 2/3 trial evaluating the addition of radiation therapy to standard immunotherapy with or without chemotherapy for PD-L1–negative adv…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: To Explore the Safety and Efficacy of Hypervision Proton Surgery for Early-stage Non-small Cell Lung Cancer [NA]
This clinical trial update outlines a study exploring the safety and efficacy of Hypervision Proton Surgery for early-stage non-small cell l…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
This ongoing clinical trial examines real-world clinical outcomes in participants with EGFR-mutated advanced non-small cell lung cancer and …
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer
Clinical trial update on adjuvant osimertinib for resected non-small cell lung cancer, focusing on recurrence gene profiles.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Phase 1/1b Study of IAM1363 in HER2 Cancers [Phase 1]
IAM1363 is being studied in a Phase 1/1b trial for HER2-related cancers, and the study is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) [Phase 3]
This Phase 3 trial compares sacituzumab govitecan plus pembrolizumab to pembrolizumab alone in metastatic non-small cell lung cancer with PD…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients [Phase 3]
A Phase III trial is evaluating taletrectinib versus standard therapy in ROS1-positive locally advanced or metastatic non-small cell lung ca…